课题基金 / 基金详情

Epigenetic regulation of cancer/germ-line antigen gene expression

Epigenetic regulation of cancer/germ-line antigen gene expression
癌症/种系抗原基因表达的表观遗传调控
批准号:
8398356
负责人:
ADAM R. KARPF
金额:
$3.39万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-08 至 2012-12-31

项目摘要

项目成果

ADAM R. KARPF的其他基金

相似基金

相关文献

中文摘要
翻译
表观遗传变化,特别是DNA甲基化的变化,在至少两个 敬重。首先,在肿瘤中,总的DMA甲基化减少,这导致异常的基因激活和 基因组不稳定。第二,CpG岛启动子高甲基化,导致转录 沉默和肿瘤抑制基因的功能失活。除了DNA的变化 甲基化,在人类癌症中观察到了其他重要的表观遗传学变化,包括变化 在组蛋白修饰模式和组蛋白修饰酶中。我们的长期目标是了解 启动和维持人类癌症异常表观遗传状态的分子机制。相遇 本研究的目的是利用肿瘤/生殖细胞(CG)抗原基因作为模型。CG抗原是一种 耐人寻味的基因家族,其在人类癌症中的异常表达似乎是表观遗传的结果 放松管制。此外,CG抗原是一种人类白细胞抗原限制性肿瘤抗原,可触发体液和细胞免疫。 癌症患者的介导性免疫反应;CG抗原导向的疫苗目前有许多 人体临床试验。因此,除了作为理解表观遗传去监管化的模型之外, 癌症、CG抗原在临床上具有相关性。我们假设CG抗原基因的表达是 受特定DNA甲基转移酶(DNMT)和组蛋白作用的表观遗传调控 甲基转移酶。为了验证这一假设,我们将追求四个互补和统一的具体目标:1) 确定DNMT抑制人癌细胞CG抗原基因表达的机制;2) 确定在人类癌症中控制CG抗原基因表达的组蛋白H3尾部赖氨酸修饰 3)确定组蛋白甲基转移酶G9a和EU-HMTasel在CG抗原基因中的作用 4)确定NY-ESO-1的表达是否与DNA有关 上皮性卵巢癌中的低甲基化。这项研究将通过改善我们的 理解为什么只有某些患者表达临床上重要的癌症疫苗靶点。此外, 这项研究将提供与理解结果和改善未来相关的关键信息 卵巢癌临床疫苗试验设计。
英文摘要
Epigenetic changes, particularly alterations in DMAmethylation, contribute to oncogenesis in at least two respects. First, overall DMA methylation is reduced in tumors, which leads to aberrant gene activation and genomic instability. Second, CpG island promoters become hypermethylated, which leads to transcriptional silencing and the functional inactivation of tumor suppressor genes. In addition to changes in DNA methylation, other important epigenetic changes have been observed in human cancer, including alterations in histone modification patterns and histone modifying enzymes. Our long-term objective is to understand the molecular mechanisms that initiate and maintain abnormal epigenetic states in human cancer. To meet this objective, we are utilizing cancer/germ-line (CG) antigen genes as models. CG antigens are an intriguing gene family whose aberrant expression in human cancer appears to result from epigenetic deregulation. In addition, CG antigens are HLA-restricted tumor antigens that trigger humoral and cell- mediated immune responses in cancer patients; CG antigen directed vaccines are currently in numerous human clinical trials. Thus, in addition to serving as a model for understanding epigenetic deregulation in cancer, CG antigens are clinically relevant. We hypothesize that CG antigen gene expression is epigenetically regulated by the action of specific DNA methyltransferases (DNMTs) and histone methyltransferases. To test this hypothesis, we will pursue four complementary and unified specific aims: 1) Determine the mechanism by which DNMTs repress CG antigen gene expression in human cancer cells; 2) Define the histone H3 tail lysine modifications that control CG antigen gene expression in human cancer cells; 3) Ascertain the role of the histone methyltransferases G9a and Eu-HMTasel in CG antigen gene regulation in human cancer cells; and 4) Determine whether NY-ESO-1 expression is associated with DNA hypomethylation in epithelial ovarian cancer. This study will impact public health by improving our understanding of why only certain patients express clinically important cancer vaccine targets. Furthermore, this study will provide key information relevant for understanding the outcome and improving the future design of clinical vaccine trials for the treatment of ovarian cancer.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2013
期刊: Cancer immunity
影响因子: --
作者: [Petra A. Link;Wa Zhang;K. Odunsi;A. Karpf]
通讯作者: Petra A. Link;Wa Zhang;K. Odunsi;A. Karpf
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
SGI-110(一种低甲基化剂)在急性髓系白血病细胞和异种移植物中的免疫调节作用。
DOI: 10.1016/j.leukres.2014.09.001
发表时间: 2014
期刊: Leukemia research
影响因子: 2.7
作者: [Srivastava,Pragya, Paluch,BenjaminE, Matsuzaki,Junko, James,SmithaR, Collamat-Lai,Golda, Karbach,Julia, Nemeth,MichaelJ, Taverna,Pietro, Karpf,AdamR, Griffiths,ElizabethA]
通讯作者: Griffiths,ElizabethA
BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
BORIS/CTCFL 表达不足以表达卵巢细胞系中的癌症种系抗原基因表达和 DNA 低甲基化。
DOI: --
发表时间: 2010
期刊: Cancer immunity
影响因子: --
作者: [Woloszynska-Read,Anna, James,SmithaR, Song,Chajoun, Jin,Boquan, Odunsi,Kunle, Karpf,AdamR]
通讯作者: Karpf,AdamR
DOI: 10.1016/j.cell.2008.11.042
发表时间: 2008-12-26
期刊: Cell
影响因子: 64.5
作者: [Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR]
通讯作者: Cairns BR
共 10 条
    Targeting RHNO1 in Ovarian Cancer
    Epigenetic regulation of cancer/germ-line antigen gene expression
    Green tea-mediated inhibition of aberrant DNA hypermethylation in prostate cancer
    Epigenetic regulation of cancer/germ-line antigen gene expression
    国内基金
    海外基金
    Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
    • 批准号:
      82371801
    • 项目类别:
      面上项目
    • 资助金额:
      47.00万元
    • 批准年份:
      2023
    • 负责人:
      周海波
    • 依托单位:
    精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
    • 批准号:
      82371770
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      宁铂涛
    • 依托单位:
    糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
    • 批准号:
      82371634
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      赵福军
    • 依托单位:
    亚低温调控颅脑创伤急性期神经干细胞Mpc2/Lactate/H3K9lac通路促进神经修复的研究
    • 批准号:
      82371379
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      冯军峰
    • 依托单位: